Breast cancer in postmenopausal estrogen-progestogen users
Lee, N.C.; Rubin, G.L.
Obstetrics and Gynecology 64(6): 832-834
1984
ISSN/ISBN: 0029-7844 PMID: 6504429 Document Number: 230945
Document emailed within 1 workday
Related Documents
Hayakawa, A. 2001: Estrogen progestogen replacement therapy for hyperlipidemia in postmenopausal women Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 3): 701-706Henrich, J.B. 1992: The postmenopausal estrogen/breast cancer controversy JAMA 268(14): 1900-1902
Byrjalsen, I.; Haarbo, J.; Christiansen, C. 1993: Role of cigarette smoking on the postmenopausal endometrium during sequential estrogen and progestogen therapy Obstetrics and Gynecology 81(6): 1016-1021
Hoffman, M.; Shapiro, S.; Kelly, J.P.; Cooper, D.; Carrara, H.; Williamson, A.; Denny, L.; Dutoit, G.; Allan, B.; Stander, I.; Rosenberg, L. 2003: Risk of invasive cervical cancer in relation to use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives American Journal of Epidemiology 157(11 Suppl): S11
Hoffman, M.; Shapiro, S.; Kelly, J.P.; Cooper, D.; Carrara, H.; Williamson, A.; Denny, L.; Dutoit, G.; Allan, B.; Stander, I.; Rosenberg, L. 2003: Risk of invasive cervical cancer in relation to use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives American Journal of Epidemiology 157(11 Suppl): S11
Hoffman, M.; Shapiro, S.; Kelly, J.P.; Cooper, D.; Carrara, H.; Williamson, A.; Denny, L.; Dutoit, G.; Allan, B.; Stander, I.; Rosenberg, L. 2003: Risk of invasive cervical cancer in relation to use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives American Journal of Epidemiology 157(11 Suppl): S11
Shapiro, S.; Rosenberg, L.; Hoffman, M.; Kelly, J.P.; Cooper, D.D.; Carrara, H.; Denny, L.E.; du Toit, G.; Allan, B.R.; Stander, I.A.; Williamson, A-Lise. 2003: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes and Control: Ccc 14(5): 485-495
Shapiro, S.; Rosenberg, L.; Hoffman, M.; Kelly, J.P.; Cooper, D.D.; Carrara, H.; Denny, L.E.; du Toit, G.; Allan, B.R.; Stander, I.A.; Williamson, A-Lise. 2003: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes and Control: Ccc 14(5): 485-495
Jirapinyo, M.; Theppisai, U.; Manonai, J.; Suchartwatnachai, C.; Jorgensen, L.N. 2003: Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women Acta Obstetricia et Gynecologica Scandinavica 82(9): 857-866
Sobczuk, A.; Pertyński, T.; Smolarz, B.; Romanowicz-Makowska, H. 2008: The analysis of estrogen receptor alpha (ER-alpha) gene Pvull and Xbal polymorphisms in postmenopausal women with breast cancer Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 25(145): 43-45
Gemzell-Danielsson, K.; van Heusden, A.M.; Killick, S.R.; Croxatto, H.B.; Bouchard, P.; Cameron, S.; Bygdeman, M. 2002: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen Human Reproduction 17(10): 2588-2593
Gemzell-Danielsson, K.; van Heusden, A.M.; Killick, S.R.; Croxatto, H.B.; Bouchard, P.; Cameron, S.; Bygdeman, M. 2002: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen Human Reproduction 17(10): 2588-2593
Peck, D.R.; Lowman, R.M. 1978: Estrogen and the postmenopausal breast. Mammographic considerations JAMA 240(16): 1733-1735
Andreoli, C.; Fiorentino, F.; Lenzi, G. 1970: Clinical experience with an estrogen-progestogen association with low estrogen content (ethinodiol-ethinylestradiol) Quaderni di Clinica Ostetrica E Ginecologica 25(1): 15-28
Thurzó, L. 1990: Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer Zentralblatt für Gynakologie 112(17): 1111-1115
Chlebowski, R.T.; Rohan, T.E.; Manson, J.E.; Aragaki, A.K.; Kaunitz, A.; Stefanick, M.L.; Simon, M.S.; Johnson, K.C.; Wactawski-Wende, J.; O'Sullivan, M.J.; Adams-Campbell, L.L.; Nassir, R.; Lessin, L.S.; Prentice, R.L. 2015: Breast Cancer After use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data from 2 Women's Health Initiative Randomized Clinical Trials JAMA Oncology 1(3): 296-305
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Wilson, D.W.; Phillips, M.J.; Holliday, H.W.; Blamey, R.W.; Simpson, H.W.; Pierrepoint, C.G.; Halberg, F.; Griffiths, K. 1983: Prolactin and breast skin temperature rhythms in postmenopausal women with primary breast cancer Chronobiologia 10(1): 21-30
Sabra, A.; Bonnar, J. 1983: Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel Journal of Reproductive Medicine 28(1 Suppl): 85-91
Calle, E.E.; Miracle-McMahill, H.L.; Thun, M.J.; Heath, C.W. 1995: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women Journal of the National Cancer Institute 87(7): 517-523